Understanding how to inhibit protein interactions in lung cancer treatment

Molecular mechanism of EGFRs protein-protein interaction inhibition by a grafted peptide in NSCLC

NIH-funded research Louisiana State Univ A&m Col Baton Rouge · NIH-11052643

This study is looking at how certain proteins help non-small-cell lung cancer grow and is working on creating new treatments that could stop these proteins from working together, which might help patients who have trouble with current therapies.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionLouisiana State Univ A&m Col Baton Rouge NIH-funded
Lab location1 site (Baton Rouge, United States)
Project IDNIH-11052643 on NIH RePORTER

What this research studies

This research focuses on the role of protein interactions in the development of non-small-cell lung cancer (NSCLC) and aims to create new peptides that can inhibit these interactions. By targeting the extracellular domains of epidermal growth factor receptors (EGFRs), the study seeks to overcome resistance to existing therapies that many NSCLC patients face. The approach involves designing sunflower trypsin inhibitor-grafted peptides that could potentially improve treatment outcomes for patients with this type of cancer. The research is particularly relevant given the high prevalence of NSCLC and the limited progress in improving survival rates over the past decade.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients diagnosed with non-small-cell lung cancer, particularly those who have shown resistance to current therapies.

Not a fit: Patients with other types of lung cancer or those who do not have non-small-cell lung cancer may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective treatments for non-small-cell lung cancer, potentially improving survival rates and quality of life for patients.

How similar studies have performed: While the approach of targeting EGFR dimerization is promising, it is still being explored and has not yet been widely tested in clinical settings.

Where this research is happening

Baton Rouge, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Animal Cancer Modelanti-cancer therapyBreast Cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.